CA-JUNIPER-NETWORKS
18.7.2024 09:31:26 CEST | Business Wire | Press release
Telxius, a leading global connectivity provider, is scaling its core and edge network infrastructure to 400G with a Converged Optical Routing Architecture (CORA) provided by Juniper Networks (NYSE:JNPR), a leader in secure AI-Native Networks. This will enable a simplified network capacity expansion and efficient delivery of enhanced connectivity to metro networks and data center interconnects (DCI). It provides connectivity across distances of around 100 km to points of presence (PoPs) across Telxius’ global footprint in Spain, the Americas, and wider Europe.
Telxius connects millions of customers globally, providing a wide range of capacity, colocation and security services, as well as direct internet connectivity through its Tier-1 IP network. Its extensive ecosystem combines fiber optic submarine cables and terrestrial backhauls together spanning 100,000+ km, almost 100 PoPs in 17 countries, plus 27 data centers. Telxius seamlessly connects customers with ultra-high capacity, low latency and resilient networking.
Telxius will migrate some of its key architecture to Juniper’s CORA and PTX Series Packet Transport Routers to deliver a network that offers robust power and space savings superior performance and automated operations. This will free up a substantial amount of reserved bandwidth and allow for flexible extension to 400G capacity. The project will create enhanced connectivity for Telxius’ customers and create a more sustainable architecture by optimizing network scalability and bandwidth efficiency.
The solution leverages leading edge technology with the use of an IP over Dense Wavelength Division Multiplexing (IPoDWDM) solution. This maximizes routing platform capacity, scales up link bandwidth, and can reach more network locations and customers whilst removing the need to manage and maintain external DWDM equipment.
Using Juniper’s CORA, Telxius will simplify the network architecture by consolidating previously siloed IP and optical network layers into a unified system leveraging IPoDWDM. Once the project is complete, Telxius expects to increase network reliability for its customers, simplify network operations and substantially reduce power consumption.
“This project is a fantastic step forward to bring added scalability and capacity to the Telxius network through 400G coherent pluggable optics, meeting our customers’ needs in today’s ever-growing digital economy. Telxius is at the forefront of innovation, ensuring reduced power consumption and a simplified network architecture to provide a better experience for our customers. We anticipate a number of vendor-agnostic solutions that could support this architecture, and we are excited to collaborate with Juniper to build a solid foundation for further network expansion,” said Carlos Dasi, CTO, Telxius.
“400G optics are a highly reliable solution to further enhance Telxius’ infrastructure to enable the best experience for customers. Telxius is leading the way for network innovation with the deployment of Juniper’s PTX and CORA, and Juniper is proud to enable this network transformation. Juniper’s optics solutions provide a simplified integration with Juniper infrastructure that allows the customer to scale up and scale out their network in line with their business goals. Built to last, this network transformation will extend Telxius’ network longevity to future-proof the business,” said Julius Francis, Senior Director of Product Marketing, Juniper Networks.
About Telxius
As the world’s needs for uninterrupted global interconnectivity continue to rise, we are preparing the road ahead. Telxius is a leading global connectivity provider that combines subsea and terrestrial networks with data centers worldwide. Its extensive ecosystem includes eight next-generation fiber optic submarine cables and terrestrial backhauls together spanning 100,000+ km, almost 100 PoPs in 17 countries, plus 25 landing stations. Telxius provides a wide range of capacity, colocation and security services, as well as direct internet connectivity through its Tier-1 IP network. With ultra-high capacity, low latency and resilient networking, Telxius seamlessly connects customers across the Americas, Europe and beyond. For more information about Telxius visit www.telxius.com.
About Juniper Networks
Juniper Networks believes that connectivity is not the same as experiencing a great connection. Juniper's AI-Native Networking Platform is built from the ground up to leverage AI to deliver exceptional, highly secure and sustainable user experiences from the edge to the data center and cloud. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on X (Twitter), LinkedIn, and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240718748438/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
